In Ewing sarcoma, targeted therapy has not changed the outcome of the patients up to now, and our observation that systemic therapy with EWS-FLI1 siRNA nanocarriers can effectively inhibit Ewing sarcoma xenograft growth has to be further studied for its potential of translation into the clinic. Here, EWSR1 is linked to Ewing sarcoma.